ArticleHuman vaccines & immunotherapeutics2026
Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The age distribution of disease-causal human papillomavirus (HPV) infections that lead to high-grade cervical intraepithelial neoplasia (CIN2+) is not well understood in Europe. The objective of this study was to estimate the age at acquisition of disease-causal HPV infection in women diagnosed with CIN2+ in Denmark, Estonia, Norway, Slovenia, and Sweden. A previously published discrete event simulation model was modified to estimate the age of disease-causal HPV infection for females diagnosed with CIN2+ by comparing predicted and observed age distributions of CIN2+ diagnoses using a chi-square goodness-of-fit test. Scenario and sensitivity analyses were also performed. The predicted median age (years) of disease-causal HPV infection was 23.69 in Denmark, 26.73 (narrow case definition for CIN2+ diagnosis) and 28.34 (broad definition) in Estonia, 29.32 in Norway, 32.03 in Slovenia, and 26.33 in Sweden. The percentage of women aged over 26 and 45 years with a predicted causal HPV infection was 42.7%/8.1% (26/45 years) in Denmark, 52.8%/9.0% (narrow definition) and 57.9%/12.7% (broad definition) in Estonia, 64.7%/11.9% in Norway, 72.3%/21.4% in Slovenia, and 51.2%/9.4% in Sweden. Model results were robust to variations in inputs and parametrization tested in scenario and sensitivity analyses. A considerable proportion (42.7-72.3%) of causal HPV infections are projected to occur in women over age 26, while 8.1%-21.4% are projected to occur in women over the age of 45. These findings highlight a need to consider HPV vaccination for previously unvaccinated women to reduce the burden of CIN2+ and cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.